Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

Abstract Background There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M‐cis‐C797S. The aim of this study was to investigate the association between different therapeutic strategies and survival outcomes among t...

Full description

Bibliographic Details
Main Authors: Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, Shuyang Zhang, Xin Ai, Shucai Zhang, Yan Wang
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Cancer Medicine
Subjects:
cis‐C797S
EGFR
non‐small cell lung cancer
resistance
treatment
Online Access:https://doi.org/10.1002/cam4.4336

Internet

https://doi.org/10.1002/cam4.4336

Similar Items